Second Sight Medical Products, Inc. (EYES) Fund Overview
Educational signal · not a buy or sell recommendation · How to read this
Beta 2.56: the stock has moved about 156% more than the S&P 500.
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 16, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerSecond Sight Medical Products, Inc. (EYES) trades at $29.25. Second Sight Medical Products, Inc. develops, manufactures, and markets implantable visual prosthetics. Sector: Healthcare.
Price as of · Last analyzed: Mar 16, 2026Analyst Coverage for EYES: EYES does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage.
Second Sight Medical Products, Inc. (EYES) Healthcare & Pipeline Overview
Second Sight Medical Products, acquired by Nano Precision Medical, focuses on developing and marketing implantable visual prosthetics for blind individuals. Their primary product is the Orion Visual Cortical Prosthesis System, targeting vision loss due to conditions like glaucoma and diabetic retinopathy. The company operates within the medical devices industry.
What Is the Investment Thesis for EYES?
Second Sight Medical Products, Inc. presents a high-risk, high-reward investment profile, primarily due to its focus on innovative but unproven technology in the visual prosthetics field. The company's success hinges on the clinical efficacy and market acceptance of the Orion Visual Cortical Prosthesis System. With a market capitalization of $0.21 billion and a negative P/E ratio of -0.32, the company's valuation is speculative, reflecting the potential of its technology rather than current profitability. A gross margin of 50.0% indicates potential for profitability if sales volume increases. The company's high beta of 2.56 suggests significant volatility relative to the broader market. Key growth catalysts include successful clinical trials, regulatory approvals, and commercialization of the Orion system. The reverse merger with Nano Precision Medical, Inc. introduces additional uncertainty and potential synergies.
Based on FMP financials and quantitative analysis
EYES Key Highlights
Market Cap: $0.21B indicates the company's size and market value.
- P/E Ratio: -0.32 reflects the company's current lack of profitability.
- Profit Margin: 15559645.8% suggests potential for high profitability if the company can scale its operations effectively.
- Gross Margin: 50.0% demonstrates the company's ability to generate revenue after accounting for the cost of goods sold.
- Beta: 2.56 indicates high volatility compared to the market.
Who Are EYES's Competitors?
EYES is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| BSGM BioSig Technologies, Inc. | $6.10 | +37.08% | $191M | — |
| CBLI Cytocom, Inc. | $3.17 | -7.31% | $226M | — |
| CRGX CARGO Therapeutics, Inc. Common Stock | $4.47 | 0.00% | $216M | — |
| INXB Inhibrx Biosciences, Inc. | $15.86 | +13.94% | $226M | — |
| MACK Merrimack Pharmaceuticals, Inc. | $15.14 | +0.10% | $224M | — |
| ABT Abbott Laboratories | $97.50 | +0.84% | $169B | 70 5-pillar |
| MDT Medtronic plc | $86.38 | -0.07% | $111B | 80 5-pillar |
| SYK Stryker Corporation | $275.43 | +0.90% | $106B | 79 5-pillar |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are EYES's Key Strengths?
Proprietary Orion Visual Cortical Prosthesis System.
- Focus on addressing unmet needs in blindness.
- Experienced management team.
- Potential for high profit margins.
What Are EYES's Weaknesses?
Limited commercial success to date.
- High research and development costs.
- Dependence on regulatory approvals.
- Small number of employees.
What Are the Key Risks for EYES?
Competition from alternative therapies for blindness.
- Regulatory delays and uncertainties.
- Product liability claims.
- Limited commercial success and financial resources.
- Dependence on key personnel.
What Threats Does EYES Face?
- Competition from alternative therapies.
- Regulatory hurdles and delays.
- Product liability risks.
- Economic downturn affecting healthcare spending.
What Are EYES's Competitive Advantages?
- Proprietary technology in visual prosthetics.
- Intellectual property protection through patents.
- First-mover advantage in the cortical stimulation field.
- Established relationships with key opinion leaders.
What Does EYES Do?
Second Sight Medical Products, Inc., founded in 1998 and headquartered in Sylmar, California, specializes in the development, manufacturing, and marketing of implantable visual prosthetics designed to restore a degree of artificial vision to blind individuals. The company's core technology centers around the Orion Visual Cortical Prosthesis System, an implanted cortical stimulation device. This system is intended to provide useful artificial vision to individuals who have lost their sight due to various conditions, including glaucoma, diabetic retinopathy, optic nerve injury or disease, and eye injury. The Orion system bypasses the damaged retina and optic nerve, directly stimulating the visual cortex of the brain. This approach aims to provide a form of artificial vision, enabling patients to perceive patterns of light and potentially navigate their environment more effectively. Second Sight's focus is on addressing the unmet needs of the sight-impaired population through innovative technological solutions. As of August 30, 2022, Second Sight Medical Products, Inc. was acquired by Nano Precision Medical, Inc., in a reverse merger transaction.
What Products and Services Does EYES Offer?
- Develops implantable visual prosthetics.
- Manufactures visual prosthetics devices.
- Markets visual prosthetics to treat blindness.
- Offers the Orion Visual Cortical Prosthesis System.
- Targets individuals blind due to glaucoma.
- Aims to help those with diabetic retinopathy.
- Provides solutions for optic nerve injury or disease.
- Addresses vision loss from eye injury.
How Does EYES Make Money?
- Develops and manufactures the Orion Visual Cortical Prosthesis System.
- Sells the Orion system to hospitals and clinics.
- Provides training and support to surgeons and patients.
- Generates revenue through the sale of implantable devices.
What Industry Does EYES Operate In?
Second Sight Medical Products operates within the medical devices industry, specifically focusing on visual prosthetics. This sector is characterized by technological innovation, high research and development costs, and stringent regulatory requirements. The market for visual prosthetics is relatively small but has the potential for significant growth as technology advances and the aging population increases. Competition includes companies developing alternative therapies for blindness and visual impairment. The industry is also influenced by advancements in neuroscience and neurotechnology.
Who Are EYES's Key Customers?
- Hospitals and clinics specializing in ophthalmology.
- Surgeons who perform retinal and cortical implants.
- Patients who are blind due to various causes.
- Research institutions conducting clinical trials.
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● Price is current
- ● No filing on record
- ● No analyst coverage
- ● This is an etf, not an operating company
MoonshotScore History
Recorded daily since 2026-08-23 · 41 snapshots
| 2026-08-23 | 43 |
| 2026-08-31 | 43 |
| 2026-09-08 | 43 |
| 2026-09-16 | 43 |
| 2026-09-24 | 43 |
| 2026-10-04 | 43 |
What changed?
The score has stayed at 43.
Over the same 30 days the stock moved +0.0%.
Key Financial Metrics
Return on assets is -64.0%, showing how much profit it generates from its asset base. A current ratio of 3.18 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -151.6%, the inverse of the P/E and a quick read on earnings relative to price.
Insider Activity
12 transactions · 11 purchases, 0 sales, 1 other transactions · 2 identified insiders · most recent available transactions. Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
EYES Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Proprietary Orion Visual Cortical Prosthesis System.
- Focus on addressing unmet needs in blindness.
- Experienced management team.
- Potential for high profit margins.
Bear Case
- Limited commercial success to date.
- High research and development costs.
- Dependence on regulatory approvals.
- Small number of employees.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
EYES Latest News
No recent news available for EYES.
EYES Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for EYES.
Price Targets
Wall Street price target analysis for EYES.
EYES MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for EYES; grades run from A+ (80-100) to F (below 30).
Leadership: Matthew Pfeffer
CEO
Matthew Pfeffer serves as the CEO of Second Sight Medical Products, managing a team of 15 employees. His background includes extensive experience in the healthcare and medical device industries. Pfeffer's expertise spans strategic planning, financial management, and operational leadership. He has a proven track record of driving growth and innovation in the medical technology sector. His leadership is focused on advancing Second Sight's mission to restore vision to blind individuals through innovative prosthetic devices.
Track Record: Under Pfeffer's leadership, Second Sight has focused on refining its Orion Visual Cortical Prosthesis System and navigating the regulatory landscape. Key milestones include securing funding for clinical trials and pursuing regulatory approvals for the Orion system. Pfeffer has also overseen the company's strategic shift towards cortical stimulation technology. The acquisition by Nano Precision Medical, Inc. occurred during his tenure.
EYES Healthcare Stock FAQ
What are the main risks for EYES?
The main risks for Second Sight Medical Products, Inc. include the limited commercial success to date, high research and development costs, dependence on regulatory approvals, and competition from alternative therapies for blindness.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
MoonshotScore is not published for this security.
Data provided for informational purposes only.
- Information is based on available data as of 2026-03-16.
- The company was acquired by Nano Precision Medical, Inc. in a reverse merger transaction.